Organizations have been working together since 2006 to identify new treatments for Huntington disease.

Evotec and the CHDI Foundation extended their Huntington disease therapeutics collaboration through to the end of 2012. The extension will provide Evotec with up to $37.5 million in research funding over the next three years.

The organizations initiated their Huntington-focused partnership in March 2006 and have since signed four agreements covering medicinal chemistry, assay development, and screening along with library synthesis and management services. 

Evotec is applying its biological science expertise to develop assays such as those designed for high-content screening against high-priority biological targets that are believed to be relevant to the future treatment of Huntington Disease for CHDI and the High Q Foundation.

Previous articleInvestigators Discover How Key Protein Leads to Neurodegenerative Diseases
Next articleReporting from J.P. Morgan Healthcare Conference